PSMA-PET Challenges Current Prostate Cancer Staging
TOPLINE:Prostate-specific membrane antigen-- positron emission tomography (PSMA-PET) identified metastatic illness in 46% of clients with high-risk prostate cancer formerly categorized as nonmetastatic by standard imaging. Outcomes were favorable in 84% of clients, with polymetastatic illness discovered in 24% of cases.METHOD:Reoccurring nonmetastatic hormone-sensitive prostate cancer is defined by increasing prostate-specific antigen (PSA) levels while ignorant or responsive to androgen deprivation treatment, without proof of transition on standard imaging.A post hoc, retrospective, cross-sectional analysis consisted of 182 clients from 4 potential research studies performed from September 2016 to September 2021, with individuals having frequent prostate cancer after extreme prostatectom...